alendronate has been researched along with Bisphosphonate Osteonecrosis in 85 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our aims were to evaluate if the risk of surgically treated ONJ increases with longer or more compliant treatment with alendronate for osteoporosis and to identify risk factors for surgically treated ONJ." | 7.85 | Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. ( Abrahamsen, B; Eastell, R; Eiken, PA; Prieto-Alhambra, D, 2017) |
| "We aimed to establish the incidence of alendronate-related osteonecrosis of the jaw (ONJ) in the southeast of Scotland, and to assess the effect of corticosteroids on it." | 7.83 | Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. ( Lopes, V; Malden, N; Ralston, S; Sammut, S, 2016) |
| "Zoledronic acid is a third-generation nitrogen-containing BP." | 5.40 | Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. ( Magremanne, M; Reychler, H, 2014) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| " Usually with alendronate the risk of bisphosphonate-related osteonecrosis of jaw (BRONJ) wears off after 12 months." | 3.96 | Osteonecrosis and spontaneous exfoliation of dental implants associated with oral bisphosphonate therapy: a case report. ( Hilal, G; Rawal, SY, 2020) |
| " Here, we show that administration of anti-resorptive agents such as the bisphosphonate alendronate accelerates osteonecrosis promoted by infectious osteomyelitis." | 3.85 | Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. ( Ishihara, K; Ishii, K; Iwakura, Y; Iwasaki, R; Kawana, H; Keneko, Y; Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morita, M; Nakagawa, T; Nakamura, M; Nakamura, S; Oike, T; Sato, Y; Watanabe, R, 2017) |
| " Our aims were to evaluate if the risk of surgically treated ONJ increases with longer or more compliant treatment with alendronate for osteoporosis and to identify risk factors for surgically treated ONJ." | 3.85 | Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. ( Abrahamsen, B; Eastell, R; Eiken, PA; Prieto-Alhambra, D, 2017) |
| "We aimed to establish the incidence of alendronate-related osteonecrosis of the jaw (ONJ) in the southeast of Scotland, and to assess the effect of corticosteroids on it." | 3.83 | Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. ( Lopes, V; Malden, N; Ralston, S; Sammut, S, 2016) |
| "The study objective was to evaluate the effect on osteoblast growth of high concentrations of three nitrogen-containing bisphosphonates (pamidronate, alendronate, and ibandronate) and one non-nitrogen-containing bisphosphonate (clodronate), using the MG-63 cell line as an osteoblast model, in order to determine the role of osteoblasts in bisphosphonate-related osteonecrosis of the jaw (BRONJ)." | 3.81 | High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. ( De Luna-Bertos, E; García-Martínez, O; Manzano-Moreno, FJ; Ramos-Torrecillas, J; Ruiz, C, 2015) |
| "To provide information on ONJ in Asian populations, this study compares the incidence and risk of ONJ between patients receiving alendronate and those receiving non-bisphosphonate osteoporosis medications in Taiwan." | 3.80 | Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. ( Kao Yang, YH; Lin, SJ; Lin, TC; Yang, CY, 2014) |
| "This study aimed to explore the possible association between osteonecrosis of the jaws (ONJ) and oral alendronate or raloxifene used for osteoporosis and to estimate its absolute and attributable risks in the Taiwanese population." | 3.80 | The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. ( Chien, JY; Chiu, WY; Juang, JM; Lee, JJ; Tsai, KS; Yang, WS, 2014) |
| " We document one case of BRONJ associated with oral administration of methotrexate, a known immunosuppressive drug used to treat rheumatoid arthritis." | 3.80 | Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report. ( Adams, L; Alsalleeh, F; Bavitz, B; Keippel, J, 2014) |
| "The patient was a 72-year-old woman with osteoporosis who had received 35 mg alendronate sodium hydrate once every week for 6 years." | 3.80 | Bisphosphonate-related osteonecrosis of the palatal torus. ( Kaneko, K; Takahashi, H, 2014) |
| " The patient suffered from osteoporosis and had been treated with oral alendronate sodium in the past." | 3.78 | The importance of a thorough medical and pharmacological history before dental implant placement. ( Abu-Tair, J; Elad, S; Yarom, N; Zadik, Y; Zaharia, B, 2012) |
| "Recently, some reports indicate that osteonecrosis of the jaws could occur after taking drugs containing hisphosphonates, including alendronate, pamidronate and zolendronate, which are widely used to treat osteoporosis and metastatic skeletal lesions in clinic." | 3.73 | [Advances in the research of bisphosphonate-associated osteonecrosis of the jaws]. ( Ji, T; Ruan, M; Zhang, CP, 2006) |
| "Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1." | 2.66 | Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020) |
| "Alendronate was the most frequently administered ARD." | 2.55 | What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. ( Aljohani, S; Ehrenfeld, M; Fliefel, R; Ihbe, J; Kühnisch, J; Otto, S, 2017) |
| "The use of osteoclast inhibitors in metastatic bone disease, increase bone mineral density and reduce the risk of fracture, patients with osteonecrosis have been reported after the chronic use of these inhibitors." | 1.51 | Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study. ( Chaurand-Lara, J; Facio-Umaña, JA; Mora-Pérez, J; Pacheco-Ruiz, L; Trejo-Campos, JL, 2019) |
| "Zoledronic acid is a third-generation nitrogen-containing BP." | 1.40 | Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. ( Magremanne, M; Reychler, H, 2014) |
| "We obtained complete control of neuropathic pain after 6 months of the patients' evolution, preserving the function of the lingual nerve in all 3 neurolysis, without causing any impact as regards to the sensitive situation before treatment." | 1.40 | Surgical neurolysis for the treatment of neuropathic pain in 2 postmenopausal women with mandibular necrosis resulting from oral bisphosphonates. ( Gandara-Rey, JM; Garcia-Garcia, A; Perez-Sayans, M; Somoza-Martin, M, 2014) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Patients with symptoms of osteoporosis, prostate cancer, or breast cancer were surveyed to determine their knowledge of bisphosphonates." | 1.38 | Awareness and education of patients receiving bisphosphonates. ( Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.18) | 29.6817 |
| 2010's | 76 (89.41) | 24.3611 |
| 2020's | 8 (9.41) | 2.80 |
| Authors | Studies |
|---|---|
| Marino, R | 1 |
| Squillacioti, A | 1 |
| Lo Giudice, G | 1 |
| Cicchiello, S | 1 |
| Scozzaro, C | 1 |
| Mummolo, S | 1 |
| De Ponte, FS | 1 |
| Nastro Siniscalchi, E | 1 |
| Amigues, C | 1 |
| Fresse, A | 1 |
| Roux, CH | 1 |
| Gauthier, S | 1 |
| Vieillard, MH | 1 |
| Drici, MD | 1 |
| Breuil, V | 1 |
| Taguchi, A | 1 |
| Tanaka, S | 2 |
| Ozaki, T | 1 |
| Arai, K | 1 |
| Mori, S | 1 |
| Ohta, H | 1 |
| Hagino, H | 1 |
| Shiraki, M | 1 |
| Nakamura, T | 1 |
| Soen, S | 1 |
| Rawal, SY | 1 |
| Hilal, G | 1 |
| Manzano-Moreno, FJ | 3 |
| Illescas-Montes, R | 2 |
| Melguizo-Rodriguez, L | 2 |
| Costela-Ruiz, VJ | 1 |
| García-Martínez, O | 3 |
| Ruiz, C | 3 |
| Ramos-Torrecillas, J | 3 |
| Lesclous, P | 1 |
| Cloitre, A | 1 |
| Catros, S | 1 |
| Devoize, L | 1 |
| Louvet, B | 1 |
| Châtel, C | 1 |
| Foissac, F | 1 |
| Roux, C | 1 |
| McCusker, S | 1 |
| May, C | 1 |
| Jakob, T | 1 |
| Tesfamariam, YM | 1 |
| Macherey, S | 1 |
| Kuhr, K | 1 |
| Adams, A | 1 |
| Monsef, I | 1 |
| Heidenreich, A | 1 |
| Skoetz, N | 1 |
| Inoue, M | 1 |
| Matsumoto, C | 1 |
| Nakajima, K | 1 |
| Kuroshima, S | 2 |
| Sawase, T | 1 |
| Morita, M | 1 |
| Iwasaki, R | 1 |
| Sato, Y | 1 |
| Kobayashi, T | 1 |
| Watanabe, R | 1 |
| Oike, T | 1 |
| Nakamura, S | 1 |
| Keneko, Y | 1 |
| Miyamoto, K | 1 |
| Ishihara, K | 1 |
| Iwakura, Y | 1 |
| Ishii, K | 1 |
| Matsumoto, M | 1 |
| Nakamura, M | 1 |
| Kawana, H | 1 |
| Nakagawa, T | 1 |
| Miyamoto, T | 1 |
| Eiken, PA | 1 |
| Prieto-Alhambra, D | 1 |
| Eastell, R | 1 |
| Abrahamsen, B | 1 |
| Aljohani, S | 1 |
| Fliefel, R | 1 |
| Ihbe, J | 1 |
| Kühnisch, J | 1 |
| Ehrenfeld, M | 1 |
| Otto, S | 1 |
| Pan, WL | 1 |
| Chen, PL | 1 |
| Lin, CY | 1 |
| Pan, YC | 1 |
| Ju, YR | 1 |
| Chan, CP | 1 |
| Hsu, RW | 1 |
| McCadden, L | 1 |
| Leonard, CG | 1 |
| Primrose, WJ | 1 |
| Chiu, WY | 2 |
| Yang, WS | 2 |
| Chien, JY | 2 |
| Lee, JJ | 3 |
| Tsai, KS | 2 |
| Khominsky, A | 1 |
| Lim, M | 1 |
| Larson, MJ | 1 |
| Oakes, AB | 1 |
| Epperson, E | 1 |
| Chew, DJ | 1 |
| Chaurand-Lara, J | 1 |
| Pacheco-Ruiz, L | 1 |
| Trejo-Campos, JL | 1 |
| Facio-Umaña, JA | 1 |
| Mora-Pérez, J | 1 |
| Abtahi, J | 3 |
| Agholme, F | 3 |
| Aspenberg, P | 3 |
| Cheng, SJ | 1 |
| Wang, JJ | 1 |
| Chiang, CP | 1 |
| Chang, HH | 1 |
| Chen, HM | 1 |
| Kok, SH | 1 |
| Kharazmi, M | 2 |
| Hallberg, P | 2 |
| Persson, U | 1 |
| Warfvinge, G | 2 |
| Berti-Couto, SA | 1 |
| Vasconcelos, AC | 1 |
| Iglesias, JE | 1 |
| Figueiredo, MA | 1 |
| Salum, FG | 1 |
| Cherubini, K | 1 |
| Wickham, N | 1 |
| Crawford, A | 1 |
| Carney, AS | 1 |
| Goss, AN | 1 |
| Albu, S | 1 |
| Di Fede, O | 1 |
| Fusco, V | 1 |
| Matranga, D | 1 |
| Solazzo, L | 1 |
| Gabriele, M | 1 |
| Gaeta, GM | 1 |
| Favia, G | 1 |
| Sprini, D | 1 |
| Peluso, F | 1 |
| Colella, G | 1 |
| Vescovi, P | 1 |
| Campisi, G | 1 |
| Lee, JY | 1 |
| Kim, IR | 1 |
| Park, BS | 1 |
| Kim, YD | 1 |
| Chung, IK | 1 |
| Song, JM | 1 |
| Shin, SH | 1 |
| Farias, DS | 1 |
| Zen Filho, EV | 1 |
| de Oliveira, TF | 1 |
| Tinôco-Araújo, JE | 1 |
| Sampieri, MB | 1 |
| Antunes, HS | 1 |
| Santos, PS | 1 |
| López-Cedrún, JL | 2 |
| Sanromán, JF | 1 |
| García, A | 1 |
| Peñarrocha, M | 1 |
| Feijoo, JF | 1 |
| Limeres, J | 1 |
| Diz, P | 1 |
| Prada García, C | 1 |
| Rodríguez Prieto, MÁ | 1 |
| Magremanne, M | 1 |
| Reychler, H | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Paiva-Fonseca, F | 1 |
| Santos-Silva, AR | 1 |
| Della-Coletta, R | 1 |
| Vargas, PA | 1 |
| Lopes, MA | 1 |
| Ulmner, M | 1 |
| Jarnbring, F | 1 |
| Törring, O | 1 |
| Entezami, P | 1 |
| McCauley, LK | 1 |
| Yamashita, J | 1 |
| Zaman, MU | 1 |
| Nakamoto, T | 1 |
| Tanimoto, K | 1 |
| Borm, JM | 1 |
| Moser, S | 1 |
| Locher, M | 1 |
| Damerau, G | 1 |
| Stadlinger, B | 1 |
| Grätz, KW | 3 |
| Jacobsen, C | 3 |
| Balint, A | 1 |
| Decoteau, C | 1 |
| Oreadi, D | 1 |
| Hamada, H | 1 |
| Matsuo, A | 1 |
| Koizumi, T | 1 |
| Satomi, T | 1 |
| Chikazu, D | 1 |
| Lin, TC | 1 |
| Yang, CY | 1 |
| Kao Yang, YH | 1 |
| Lin, SJ | 1 |
| Sehn, FP | 1 |
| Dias, RR | 1 |
| de Santana Santos, T | 1 |
| Xavier, SP | 1 |
| Chatterjee, R | 1 |
| Bajoria, R | 1 |
| Shah, FT | 1 |
| Porter, JB | 1 |
| Fedele, S | 1 |
| Kaehling, Ch | 1 |
| Streckbein, P | 1 |
| Schmermund, D | 1 |
| Henrich, M | 1 |
| Burchert, D | 1 |
| Gattenloehner, S | 1 |
| Howaldt, HP | 1 |
| Wilbrand, JF | 1 |
| Gennaro, P | 1 |
| Chisci, G | 1 |
| Aboh, IV | 1 |
| Gabriele, G | 1 |
| Cascino, F | 1 |
| Iannetti, G | 1 |
| Juang, JM | 1 |
| Garcia-Garcia, A | 2 |
| Somoza-Martin, M | 1 |
| Gandara-Rey, JM | 1 |
| Perez-Sayans, M | 1 |
| Michaëlsson, K | 1 |
| Alsalleeh, F | 1 |
| Keippel, J | 1 |
| Adams, L | 1 |
| Bavitz, B | 1 |
| Kaneko, K | 1 |
| Takahashi, H | 1 |
| De Luna-Bertos, E | 1 |
| Skoglund, K | 1 |
| Hjortdal, O | 1 |
| Strømsøe, K | 1 |
| Eriksen, EF | 1 |
| Ribeiro, NR | 1 |
| Silva, Lde F | 1 |
| Santana, DM | 1 |
| Nogueira, RL | 1 |
| Sammut, S | 1 |
| Malden, N | 3 |
| Lopes, V | 2 |
| Ralston, S | 1 |
| Conte, N | 1 |
| Spolidorio, LC | 2 |
| Andrade, CR | 2 |
| Esteves, JC | 1 |
| Marcantonio, E | 2 |
| Sánchez, A | 1 |
| Blanco, R | 1 |
| Han, XD | 1 |
| Tang, MB | 1 |
| Oon, HH | 1 |
| Loh, S | 1 |
| Bauer, JS | 1 |
| Beck, N | 1 |
| Kiefer, J | 1 |
| Stockmann, P | 1 |
| Wichmann, M | 1 |
| Eitner, S | 1 |
| Fitzpatrick, SG | 1 |
| Stavropoulos, MF | 1 |
| Bowers, LM | 1 |
| Neuman, AN | 1 |
| Hinkson, DW | 1 |
| Green, JG | 1 |
| Bhattacharyya, I | 1 |
| Cohen, DM | 1 |
| Vestergaard, P | 1 |
| Schwartz, K | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 1 |
| Pinholt, EM | 1 |
| Ohe, JY | 1 |
| Kwon, YD | 1 |
| Lee, HW | 1 |
| Martins, MA | 1 |
| Martins, MD | 1 |
| Lascala, CA | 1 |
| Curi, MM | 1 |
| Migliorati, CA | 1 |
| Tenis, CA | 1 |
| Marques, MM | 1 |
| Moretti, F | 1 |
| Pelliccioni, GA | 1 |
| Montebugnoli, L | 1 |
| Marchetti, C | 1 |
| Zadik, Y | 2 |
| Benoliel, R | 1 |
| Fleissig, Y | 1 |
| Casap, N | 1 |
| Sandberg, O | 2 |
| Voss, PJ | 1 |
| Joshi Oshero, J | 1 |
| Kovalova-Müller, A | 1 |
| Veigel Merino, EA | 1 |
| Sauerbier, S | 1 |
| Al-Jamali, J | 1 |
| Lemound, J | 1 |
| Metzger, MC | 1 |
| Schmelzeisen, R | 1 |
| Metzler, P | 2 |
| Rössle, M | 2 |
| Obwegeser, J | 1 |
| Zemann, W | 2 |
| Ghazali, N | 1 |
| Collyer, JC | 1 |
| Tighe, JV | 1 |
| Diniz-Freitas, M | 1 |
| Fernández-Sanromán, J | 1 |
| Fernández-Feijoo, J | 1 |
| Diz-Dios, P | 1 |
| O'Ryan, FS | 1 |
| Lo, JC | 1 |
| Aguirre, JI | 1 |
| Akhter, MP | 1 |
| Kimmel, DB | 1 |
| Pingel, JE | 1 |
| Williams, A | 1 |
| Jorgensen, M | 1 |
| Kesavalu, L | 1 |
| Wronski, TJ | 1 |
| Cole-Hawkins, H | 1 |
| Fyfe, E | 1 |
| Price, C | 1 |
| Pring, M | 1 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Abu-Tair, J | 1 |
| Yarom, N | 1 |
| Zaharia, B | 1 |
| Elad, S | 1 |
| Schaudinn, C | 1 |
| Gorur, A | 1 |
| Webster, P | 1 |
| Jones, AC | 1 |
| Neely, M | 1 |
| Jelliffe, RW | 1 |
| Le, AD | 1 |
| Sedghizadeh, PP | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Ohbayashi, Y | 1 |
| Miyake, M | 1 |
| Sawai, F | 1 |
| Minami, Y | 1 |
| Iwasaki, A | 1 |
| Matsui, Y | 1 |
| Conte Neto, N | 1 |
| S Bastos, A | 1 |
| Guimarães, M | 1 |
| Hasegawa, T | 1 |
| Ri, S | 1 |
| Umeda, M | 1 |
| Komatsubara, H | 1 |
| Kobayashi, M | 1 |
| Shigeta, T | 1 |
| Yoshitomi, I | 1 |
| Ikeda, H | 1 |
| Shibuya, Y | 1 |
| Asahina, I | 1 |
| Komori, T | 1 |
| Schipmann, S | 1 |
| von Jackowski, J | 1 |
| Obwegeser, JA | 1 |
| Ruan, M | 1 |
| Ji, T | 1 |
| Zhang, CP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695] | Phase 2 | 0 participants | Interventional | 1999-03-31 | Terminated | ||
| Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558] | Phase 2 | 44 participants | Interventional | 2001-12-31 | Completed | ||
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001] | Phase 3 | 645 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650] | Phase 2 | 111 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646] | Phase 3 | 227 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918] | Phase 2 | 300 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620] | Phase 3 | 1,904 participants (Actual) | Interventional | 2006-04-01 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment[NCT03040778] | Phase 3 | 100 participants (Anticipated) | Interventional | 2018-04-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 37.9 |
| Placebo + Androgen Deprivation Therapy | 36.0 |
"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 10.6 |
| Placebo + Androgen Deprivation Therapy | 9.2 |
Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 31.9 |
| Placebo + Androgen Deprivation Therapy | 28.8 |
Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 25 |
| Denosumab 180 mg Q12W | 32 |
| Denosumab 180 mg Q4W | 35 |
Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 0 |
| Denosumab 180 mg Q12W | 0 |
| Denosumab 180 mg Q4W | 0 |
Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -40.68 |
| Denosumab 180 mg Q12W | -76.74 |
| Denosumab 180 mg Q4W | -68.39 |
Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -32.91 |
| Denosumab 180 mg Q12W | -69.09 |
| Denosumab 180 mg Q4W | -41.68 |
Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Days (Median) |
|---|---|
| Bisphosphonate IV Q4W | 65 |
| Denosumab 180 mg Q12W | 9 |
| Denosumab 180 mg Q4W | 10 |
Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 10 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 28 |
Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 13 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 23 |
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Events (Number) |
|---|---|
| Zoledronic Acid | 584 |
| Denosumab | 494 |
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
10 reviews available for alendronate and Bisphosphonate Osteonecrosis
| Article | Year |
|---|---|
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2017 |
Bisphosphonate-induced osteonecrosis of the ear canal: our experience and a review of the literature.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2018 |
"Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review.
Topics: Aged; Alendronate; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2018 |
Bisphosphonate-associated osteonecrosis of the auditory canal.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2013 |
Alendronate-associated osteonecrosis of the jaws: a review of the main topics.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; H | 2014 |
[Risk assessment in patients undergoing osseous antiresorptive therapy in dentistry. An update].
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2013 |
Posttransplant lymphoproliferative disorder presenting as a nonhealing extraction socket: a case report and review of the literature.
Topics: Administration, Oral; Alendronate; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bi | 2012 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Osteopathology associated with bone resorption inhibitors - which role does Actinomyces play? A presentation of 51 cases with systematic review of the literature.
Topics: Actinomyces; Actinomycosis; Adult; Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Hum | 2013 |
3 trials available for alendronate and Bisphosphonate Osteonecrosis
| Article | Year |
|---|---|
Reliability of early stage symptoms/clinical findings of osteonecrosis of the jaw: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2023 |
A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Alendronate; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial | 2011 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
72 other studies available for alendronate and Bisphosphonate Osteonecrosis
| Article | Year |
|---|---|
Medication-Related Osteonecrosis of the Jaw: 14 Years' Retrospective Study on Pathogenetic Trigger Events.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2022 |
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2023 |
Osteonecrosis and spontaneous exfoliation of dental implants associated with oral bisphosphonate therapy: a case report.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2020 |
Impact of bisphosphonates on the proliferation and gene expression of human fibroblasts.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Differentiation; Cell Prolifer | 2019 |
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2020 |
A cutaneous presentation of bisphosphonate-related osteonecrosis of the jaw.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2020 |
Alendronate/dexamethasone combination therapy worsens soft and hard tissue wound healing around implants in rat maxillae.
Topics: Alendronate; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation | 2021 |
Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis.
Topics: Alendronate; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation | 2017 |
Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis | 2017 |
Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2017 |
Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Morphogenetic Protein 2; Bone | 2018 |
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2018 |
Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat.
Topics: Alendronate; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cat Diseases; Cats; Diphos | 2019 |
Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon | 2019 |
Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; | 2013 |
Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Amoxicillin; Amoxicillin-Potassiu | 2013 |
Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats.
Topics: Adrenal Cortex Hormones; Alendronate; Animals; Biopsy, Needle; Bisphosphonate-Associated Osteonecros | 2014 |
Bisphosphonate-associated osteonecrosis of the external auditory canal.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diagnosis, Differential; Ear | 2013 |
Bisphosphonates and osteonecrosis of the maxilla.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; F | 2014 |
Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases.
Topics: Administration, Oral; Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Alendronate; Bi | 2013 |
Effect of low-level laser therapy on oral keratinocytes exposed to bisphosphonate.
Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Line, Tumor; Cell M | 2015 |
Clinical and image findings in bisphosphonate-related osteonecrosis of the jaws.
Topics: Adult; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Debridement; Diphospho | 2013 |
Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Alendronate; Bisphosphonate-Associated Osteonec | 2013 |
Submandibular cutaneous fistula.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2013 |
Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Alendronate; Antioxidants; Bisphosphonate-Associated Osteonecrosis of the J | 2014 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated O | 2014 |
Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing.
Topics: Alendronate; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density | 2014 |
A retrospective study of digital subtraction technique to detect sclerotic changes in alveolar bone on intraoral radiographs of bisphosphonate-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alveolar Process; Anatomic Landmarks; Bisphosphonate-As | 2013 |
A clinico-pathologic correlation.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2013 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Ass | 2014 |
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2014 |
Oral bisphosphonate-related mandible fracture.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2014 |
High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major.
Topics: Alendronate; beta-Thalassemia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Cons | 2014 |
Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw.
Topics: Abscess; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation | 2014 |
"Implant surgery triggered" bisphosphonate-related osteonecrosis of the jaws (BRONJ).
Topics: Administration, Oral; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Dental | 2014 |
The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis | 2014 |
Surgical neurolysis for the treatment of neuropathic pain in 2 postmenopausal women with mandibular necrosis resulting from oral bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cranial Ne | 2014 |
Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2014 |
Bisphosphonate-associated osteonecrosis of jaw reoccurrence after methotrexate therapy: a case report.
Topics: Aged; Alendronate; Amoxicillin; Anti-Bacterial Agents; Apicoectomy; Arthritis, Rheumatoid; Bisphosph | 2014 |
Bisphosphonate-related osteonecrosis of the palatal torus.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2014 |
High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis.
Topics: Alendronate; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservatio | 2015 |
Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Fract | 2015 |
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates].
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Hip Fractur | 2015 |
[Re: Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates].
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Hip Fractur | 2015 |
Bisphosphonate-Related Osteonecrosis of the Jaw After Tooth Extraction.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bispho | 2015 |
Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2016 |
Experimental osteonecrosis: development of a model in rodents administered alendronate.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of t | 2016 |
Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2017 |
Discharging nodule on the jaw.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2016 |
Pharmacology: Discontinuation of bisphosphonates.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; D | 2017 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Os | 2012 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the | 2012 |
An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2012 |
Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.
Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; C | 2012 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon | 2012 |
Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: a new etiology for the numb-chin syndrome.
Topics: Aged; Alendronate; Amitriptyline; Analgesics, Non-Narcotic; Bisphosphonate-Associated Osteonecrosis | 2012 |
Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; | 2012 |
Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2012 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents | 2013 |
Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera.
Topics: Aged, 80 and over; Alendronate; Aspirin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone De | 2013 |
Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Densi | 2012 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Age | 2012 |
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.
Topics: Alendronate; Animals; Apoptosis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Cell Count; Dip | 2012 |
The importance of a thorough medical and pharmacological history before dental implant placement.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Age | 2012 |
Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Topics: Acid Phosphatase; Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bisphosphonate-A | 2013 |
Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw.
Topics: Administration, Topical; Alendronate; Animals; Anti-Inflammatory Agents; Bisphosphonate-Associated O | 2013 |
Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of t | 2013 |
The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Antibiotic Prophylaxis; Bisphosph | 2013 |
[Advances in the research of bisphosphonate-associated osteonecrosis of the jaws].
Topics: Alendronate; Biomedical Research; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density C | 2006 |